Quantcast

Latest Fluticasone/salmeterol Stories

2009-12-22 07:00:00

WALTHAM, Mass., Dec. 22 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that since the 2008 retrospective analysis of patient-level claims data, Boehringer Ingelheim/Pfizer's Spiriva has closed the gap in patient share between itself and GlaxoSmithKline's Advair in newly diagnosed chronic obstructive pulmonary disease (COPD) patients. Although Advair's patient share in the first line is...

2009-12-02 17:52:00

NEW YORK, Dec. 2 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: Global Markets for Asthma and COPD Drugs http://www.reportlinker.com/p0166826/Global-Markets-for-Asthma-and-COPD-Drugs.html Provides an in-depth analysis of the global market for medications that treat asthma and chronic obstructive pulmonary disease Contains global market forecasts through 2014 for medications that treat asthma and chronic obstructive pulmonary...

2009-08-24 15:30:00

RESEARCH TRIANGLE PARK, N.C., Aug. 24 /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE: GSK) is advising that two lots of Advair Diskus(R) (fluticasone propionate and salmeterol inhalation powder) medication were stolen on August 2 from the company's distribution facility near Richmond, Virginia. Medicine in the stolen cartons could represent a health risk because it has been removed from the legitimate supply chain and the storage conditions under which the stolen products were held are...

2009-06-23 07:00:00

Emerging Combination Products from GlaxoSmithKline/Theravance, Boehringer Ingelheim and Novartis Will Drive Growth, According to a New Report from Decision Resources WALTHAM, Mass., June 23 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that a 28 percent increase in the diagnosed prevalent population will drive growth in the chronic obstructive pulmonary disease (COPD) drug market in the United...

2009-06-01 07:00:00

Most Influential COPD Brand Messages Are Those That Highlight Maintenance of Daily Activities, Ease of Breathing and Reduction of Symptoms Decision Resources Introduces New Brand Perception Series WALTHAM, Mass., June 1 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that surveyed pulmonologists and patients view Boehringer Ingelheim/Pfizer's Spiriva as the best and second-best chronic...

2009-02-10 09:01:27

Newly published research out of Wake Forest University School of Medicine finds that a popular class of anti-inflammatory inhalers significantly increases the risk of pneumonia in patients with Chronic Obstructive Pulmonary Disease (COPD).The study appears in this month's issue of Archives of Internal Medicine and focuses on the incidence of pneumonia in patients with COPD who were exposed to inhaled corticosteroid drugs, either alone or in combination with other drugs.COPD is a progressive...

2008-12-22 12:15:00

JEFFERSON, N.C., Dec. 22 /PRNewswire/ -- Next Safety has developed a proprietary platform that delivers nicotine and a number of other drugs including albuterol and the components of Advair(TM), fluticasone propionate and salmeterol xinofoate, in air timed to the user's inhalation. Certain US patents for the chemical components of Advair(TM) expired September 2008. Next Safety's platform has numerous advantages over current methods used for delivering these significant asthma...

2008-12-15 12:20:00

JEFFERSON, N.C., Dec. 15 /PRNewswire/ -- Inhalers used for delivering albuterol, a fast-acting bronchial dilator, currently use propellants such as ozone-depleting CFC's, which are banned by the FDA beginning December 31st, 2009, or replacement HFA's. Both propellants are also used as industrial refrigerants and eject the medicine, albuterol, at near-supersonic speeds. The Next Safety device supplies medication in a stream of air by ejecting the medication from a microfluidic pump...

2008-12-12 05:12:52

A U.S. Food and Drug Administration panel said the drugs Serevent and Foradil shouldn't be used for treating asthma. The panel said Serevent and Foradil are often prescribed inappropriately by doctors and used incorrectly by patients, The New York Times said Thursday. The drugs are longer-acting beta agonists intended to prevent attacks but have been shown to increase the risk of more severe attacks if used without a steroid, the newspaper said. The panel ruled that Advair and Symbicort...

2008-12-11 16:04:00

WASHINGTON, Dec. 11 /PRNewswire-FirstCall/ -- The following is GlaxoSmithKline's (NYSE: GSK) statement regarding recommendations of a combined Advisory Committee to the FDA on the use of asthma medicines containing long-acting beta agonists, including GSK's Serevent(R) (salmeterol) and Advair(R) (salmeterol/fluticasone proprionate). "We welcome the committee's endorsement of Advair as a safe and effective treatment for asthma in adults and children," said Dr. Ellen Strahlman, Chief...


Word of the Day
vermicular
  • Like a worm in form or movement; vermiform; tortuous or sinuous; also, writhing or wriggling.
  • Like the track or trace of a worm; appearing as if worm-eaten; vermiculate.
  • Marked with fine, close-set, wavy or tortuous lines of color; vermiculated.
  • A form of rusticated masonry which is so wrought as to appear thickly indented with worm-tracks.
This word ultimately comes from the Latin 'vermis,' worm.
Related